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under the CC BY-NC-ND license (http:Abstract With over 70% of hemodialysis (HD) patients, aged 55 years, having moderate to
severe chronic cognitive impairment (CI), in an increasingly aging population, the need to stop
this cognitive decline is paramount. CI amongst HD patients raises patient safety concerns,
while limiting their ability to understand information such as medical advice and their
decision-making ability. Unfortunately, the data available on assessment of cognition in HD pa-
tients and interventions utilized remain extremely limited. This paper discusses assessment of
cognition, the theories of CI in HD patients, and current literature on cognitive interventions in
chronic disease, with many not applicable to the HD population. An encouraging psychological
intervention called cognitive stimulation therapy helps improve cognition as well as social
skills in CI. This is the first review article discussing the possibility of cognition stimulation dur-
ing HD which has not been investigated previously. With cognitive stimulation therapy showing
improvements in cognition at 6-month follow-up, as well as being recommended by the Na-
tional Institute for Health and Care Excellence for use in dementia, we suggest the need to
study whether this therapy has any effect on cognition in HD patients both in short term, with
respect to daily activities and decision making, and in long term, with respect to the possibility
of reducing the risk of dementia.
在 55歲或以上的血液透析 (HD)病人間,逾 70%有中至重度的慢性認知障礙 (CI),在目前老年化
的人口中, 這是必須要解決的問題。在接受 HD 後, CI 可引發病人安全的隱憂, 同時亦限制患者接
受資訊如醫囑、及決策的能力。然而, 至今關於 HD 病人認知功能與改善方案的數據仍非常有
限。本文探討了認知功能的評估方法、及 CI 發生於 HD 的相關理論, 亦回顧了目前有關慢性病中
認知功能改善方案的文獻, 雖然很多並不特定於 HD 病人群。我們注意到一種稱為認知刺激療法
(cognitive stimulation therapy, CST) 的心理治療方案, 可望改善 CI 患者的認知功能和社交技
能。本文將首度就這種療法對 HD 病人的效應作出探討。事實上, CST 經證實可於 6 個月期間達
到認知功能的改善, 亦是英國 NICE (National Institute for Health and Care Excellence) 建議的
失智症療法, 我們認為有需要研究 CST 對 HD 病人認知功能的影響, 不論是在短期 (日常活動及
決策能力)、或長期層面 (失智症的預防)。Heartlands Hospital, Bordesley Green East, Birmingham B95SS, United Kingdom.
artofengland.nhs.uk (J. Baharani).
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Dementia is a chronic illness causing a global loss in
cognition, with impairment of memory and at least one
other cognitive domain, limiting daily functioning.1 A pre-
cursor is cognitive impairment (CI) with deterioration
beyond that expected from normal aging, but with main-
tenance of daily routines and independence typically.
The incidence of cognitive decline is increasing world-
wide, with interventions to delay this decline becoming
increasingly important. The prevalence of CI in the UK in
the Medical Research Council (MRC) study was 18%.2
Cognitive functions have been shown to decline in pa-
tients on long-term hemodialysis (HD), with 70% of HD pa-
tients, aged 55 years, having moderate to severe chronic
CI.3 With recurrent acute insults on cognition during HD
being postulated to lead to long-term decline, researchers
and clinicians have raised concerns about patients’ safety
immediately after HD regarding activities such as driving
and everyday living, especially for those who live on their
own.4 CI also limits patients’ ability to understand infor-
mation such as medical advice, reduces their decision-
making ability, worsens quality of life, and is associated
with higher rates of mortality.
This review explores the link between CI and HD, and
investigates whether therapeutic interventions such as
cognitive stimulation therapy (CST) can delay this decline
in future.Table 1 Cognitive assessment tools that have been used in stu
Cognitive
assessment tool
Cognitive domains
tested
Time to
complete (min)
Sen
Mini Mental State
Examination
Orientation
Recall
Attention
Visuospatial
8 71e
Montreal Cognitive
Assessment
Orientation
Visuospatial
Recall
Attention
Verbal fluency
Executive function
10 100
Mini-Cog Visuospatial
Recall
Executive function
4 76/
Clock drawing test Visuospatial
Executive function
3 85/
Six-item cognitive
impairment
test
Recall
Orientation
Attention
4 90/
Addenbrooke’s
cognitive
assessment
revised
Orientation
Attention
Memory
Verbal fluency
Language
Visuospatial
10e20 88/Literature search strategy
A review was carried out between March and September
2014. Key terms such as hemodialysis, cognitive impair-
ment, and cognitive stimulation, with BOOLEAN operator
terms AND and IN, were used. PubMed and Google Scholar
were the two databases used to carry out the search.Assessing cognition in HD patients
Many different cognitive assessment tools have been used
to assess cognition in HD patients, with the Mini Mental
State Examination (MMSE) being used most frequently
worldwide. The ideal test for HD patients’ needs to be short
in duration, have different versions to allow monitoring of
change, be applicable in a clinical setting, be applicable to
different ethnic groups, and be comparable with other
studies. Table 1 shows many key cognitive assessment tools
used in studies to date, with sensitivity and specificity for
dementia and comments on the advantages/disadvantages
of each. Unfortunately, no studies have validated these
cognitive assessment tools in HD against a clinical diagnosis
of dementia.
Despite being used most commonly, the MMSE does not
detect executive changes, which are common among pa-
tients with end-stage renal disease (ESRD). Montreal
Cognitive Assessment (MOCA) and six-item cognitivedies on dementia with their sensitivity and specificity.
sitivity/specificity Overview
92/56e96 Limited ability to test right parietal
functions and identification of non-
Alzheimer’s disease dementia
/87 Three different versions and an easily
available online version in a number of
languages. Tests executive functions
89 Developed for primary care with no
language/education bias
85 Removes intellect and language bias;
however, this requires drawing, which is
limited by the placement of the fistula,
joint disease, and visual acuity
100 High sensitivity in mild dementia
82 Takes longer to complete, but can
differentiate between degenerative and
affective disorders
6 M. Patel et al.impairment test are better at detecting mild CI than the
MMSE,5 and MOCA easily allows follow-up in non-Caucasians
(who may not speak English), who constitute over 60% of
the HD population in some centers in the UK.
Current literature on HD and cognition
Over the last 2 decades, the association between HD and CI
has increasingly been researched. Table 2 shows studies
assessing cognitive changes among HD patients along with
the results obtained.
Data on the effect of HD on cognition over a longer term
following completion of an HD session are limited. Murray
et al6 found that cognition improved 1 hour post-HD
completion and was best both prior to HD and 1 day
after. Evoked potential latency on cognitive testing has
been shown to decrease during the 24 hours after HD,
before increasing at 66 hours post-HD.7Table 2 Studies assessing cognitive changes among HD
patients with the overall results.
Study Results
Abdelrahman
et al (2014)51
Among older HD patients, 43% had mild
cognitive impairment, 23% mild
dementia, 8.5% moderate dementia, and
7.4% severe dementia.
Costa et al
(2014)8
After HD, patients showed psychomotor
slowing and slower reaction times.
Deterioration was observed in the
executive function, timed attention, and
psychomotor speed after HD.
Jung et al
(2013)52
HD patients scored lower K-MMSE
(p Z 0.01) and higher K-BDI (p Z 0.003)
than the peritoneal dialysis group.
Nasser et al
(2012)53
Upon testing cognition, Stage 3 CKD
scored better than Stage 4 CKD, which
was worse than HD patients.
Ogadiri et al
(2011)54
There was an 18.8% prevalence of CI in
HD patients.
Tamura and
Larive
(2010)23
Within HD patients, 16% had global
cognitive impairment, while 29% had
impaired executive function.
Pereira et al
(2007)55
They suggest that despite normal MMSE
scores, mild cognitive impairment may
be prevalent among HD patients.
Popovic et al
(2006)56
A 2-y repeat in MMSE scores did not show
cognitive decline among HD patients.
Murray et al
(2006)57
Among HD patients, 13.9% had mild,
36.1% moderate, and 37.3% severe
cognitive impairment.
Kurella et al
(2004)58
A graded relationship was observed
between the severity of CKD and
cognitive function.
Sehgal et al
(1997)9
Within HD patients, 22% had mild mental
impairment and 8% moderateesevere
mental impairment.
CI Z cognitive impairment; CKD Z chronic kidney disease;
HD Z hemodialysis; K-BDI Z Korean version of the Beck
Depression Inventory; K-MMSE Z Korean version of the MMSE;
MMSE Z Mini Mental State Examination.A study in 2014 involving 99 patients was the first study
to show that language and delayed recall domains of
cognition all significantly declined during HD, before
returning close to the baseline about 1 week later (un-
published data, Patel et al, 2014). It also showed no sig-
nificant association between cognitive changes and
physiological parameters. Costa et al8 showed that a mi-
nority of HD patients had significant intraindividual cogni-
tive changes after HD, mainly in their timed attention,
psychomotor speed, and executive function.
There are a number of limitations associated with the
studies described. The sample sizes were generally small,
and the use of a wide range of cognitive measuring tools
made comparisons difficult. Patients were of different age
groups, with different renal disease etiologies, and
different vintages and time frames of HD treatment.
Importantly, there also appears to be an underdiagnosis
of CI in HD patients; only in 15% of those with CI, it was
previously identified, as evident from their medical re-
cords.9 In the Dialysis Outcomes and Practice Patterns
Study, a large multicenter observational study of HD pa-
tients running in five continents, in only 4% of HD patients a
diagnosis of dementia was documented.10Theories for cognitive decline in HD patients
HD patients often have underlying vascular disease with a
high incidence of chronic diseases, such as hypertension
and diabetes, alongside acute events such as strokes,
which contribute to CI. Numerous theories have been
postulated to explain the causes of this cognitive decline.
Among HD patients, vascular CI and mixed vascular and
Alzheimer’s disease are more frequent than Alzheimer’s
disease.11 This leads to the hypothesis of recurrent cere-
bral ischemia causing CI. Ischemia may result from mac-
rovascular disease; among 151 HD patients with acute
strokes, 34% suffered either during or within 30 minutes of
HD.12 Vertebrobasilar infarcts were significantly more
common among HD patients, which may result from
ischemia in watershed cerebral territories. Strokes are up
to nine times more common among HD patients, which
doubles the risk of dementia in these patients.13 Positron
emission tomography scans have also shown reduced ce-
rebral blood flow and oxygen metabolism in HD patients,
while the instability in blood pressure with fluid loss and
hemoconcentration also induces cerebral hypoperfusion.
Intradialytic hypotension and coronary ischemia cause
myocardial stunning in HD patients, one hypothesis is that
recurrent cerebral ischemia causes cerebral stunning,
inducing CI. HD patients also experience five times more
silent strokes, which is associated with cognitive decline
and dementia.14 They are also at an increased risk of white
matter disease, which was associated with deficits in ex-
ecutive cognitive domains in the Rotterdam study and
cardiovascular health studies, indicative of a subcortical
vascular deficit.15
An additional theory is that recurrent delirious episodes
escalate the dementia risk. This occurs because of a
“dialysis disequilibrium” syndrome resulting from cerebral
edema secondary to fluid and electrolyte changes.16 It is
also possible that these acute physiological changes can
Cognitive impairment in hemodialysis 7trigger inflammatory responses in HD patients, similar to
that in patients undergoing cardiopulmonary bypass who
have declined cerebral perfusion and raised inflammatory
and neurodegenerative markers.17
Two disorders have been described while discussing de-
mentia risk in dialysis. Uremic encephalopathy involves
oxidative stress, uremic toxins, and hormonal imbalance.
Symptoms can include tremors, multifocal myoclonus, and
seizures,18 but this encephalopathy responds to HD. Dialysis
encephalopathy syndrome is triggered by aluminum
toxicity, with patients presenting with a slurred speech,
dysarthria, and myoclonic spasms. The reduction in the use
of aluminum hydroxide and correction of phosphate
depletion prevented this syndrome, which is now a rare
phenomenon.19
Numerous risk factors have been linked to cognitive
decline in the general population, including older age,
lipids, and the APO4 allele. HD patients share the same risk
factors, except for stronger cardiovascular risk factors. In
the Dialysis Outcomes and Practice Patterns Study cohort,
increasing age, low education level, and race were inde-
pendently associated with dementia.20 One key risk factor
is anemia, with cognition being shown to increase following
erythropoietin therapy in HD patients to improve the he-
moglobin level.21 An increasing length of HD treatment has
also been shown to be associated with CI.22 Medications, in
particular H1-receptor antagonists and opioids, have been
considered as reversible causes of diminished executive CI
in ESRD.23Implications of CI in HD patients
It seems inevitable that CI will occur in the natural history
of HD patients. Whatever the trigger may be, it seems
prudent to limit the progression of CI in this group of
patients.
Many of the patients receive HD in a hospital environ-
ment under the supervision of trained staff, but there
remain implications for patients despite this. It is not un-
common for HD patients to be reviewed by medical staff,
nurses, or members of the renal multidisciplinary team
while they are undergoing dialysis, which may be to reduce
the number of visits to the hospital or because it is simply
easier to logistically do so. Whatever be the reason, the
ability of patients to harness and assimilate the informa-
tion/advice given to them during an HD session must be
questioned, especially in case of those who have an acute
fall in CI during treatment. Noncompliance with the advice
given remains a major problem in HD patients, and one has
to wonder how much of this stems from simply not
digesting the information given by the health care
professional.
Many of the patients receiving HD travel home, often
alone, with some choosing to drive, and reach home late at
night to an empty house with no carer. If there has been an
acute drop in CI during the course of treatment, the safety
of the patient in case of an emergency has to be ques-
tioned, and then there arises an implication that those who
are at a high risk of CI on HD should be dialyzed during the
day so that they may recover sufficiently before they reach
home or while they are at home.Significance of CI in HD patients
Few studies have assessed the significance of CI in ESRD.
Among 336 HD patents, Sehgal et al9 found that low MMSE
scores were independently associated with an increase in
hospital days and technician caring after HD. Lower scores
on cognitive function have been shown to be independently
related to mortality and hospitalizations.24 In a UK study
involving 145 prevalent HD patients, the 7-year survival
rate was 49% in those with coexisting CI compared to 83.2%
in those without CI.25Duty of health care professionals
If CI in HD is a continuum, then the health care professional
providing care to the patient should diagnose this and
counsel the patient on further implications for the future.
Dialysis, although a treatment for life, sometimes requires
cessation of therapy if the patient requests to withdraw, if
there is obvious failure to thrive, or most commonly on the
basis of medical grounds. Advance care planning for HD
patients, therefore, is recommended at some stage during
their dialysis journey, and it would therefore be sensible to
initiate this before CI sets in. This again will bring its own
set of practical and ethical implications.
Now, let us consider the case of those patients who
choose to have HD at home. Although this is done usually
with the help of a carer or partner, for those looking after
these patients, it is not uncommon to be privy to the fact
that many patients actually dialyze alone once the process
of dialysis has started, with the partner often coming back
toward the end of the session to ensure that all is well.
There is also an increasing trend toward solo home HD,
where the patients dialyze on their own with no carer being
present. This is of course subject to the fitness of the pa-
tient, but still is a matter of concern for those having acute
drops in CI during an HD session.Ways to improve cognition during HD
Currently, the data on ways to improve CI among HD pa-
tients are lacking. Cholinesterase inhibitors and methyl D-
aspartate receptor antagonists have been made available
for treatment of dementia with an approximate 6-month
cognitive decline delay, but the safety of these agents in
ESRD is unknown. Treatment with high-dose vitamin B,
which lowers homocysteine level, had no effect on cogni-
tion in ESRD. Moreover, an increased Kt/V was shown to
result in a worse cognitive function in HD patients.
Erythropoietin therapy used to improve hematocrit has
been shown to improve cognitive function in patients un-
dergoing HD.26 Despite approximately one-third of male
and two-thirds of female HD patients being anemic, not all
patients require erythropoietin, and complications include
thrombosed fistula and hypertensive episodes. A recent
study with 12 young HD patients showed that daily
nocturnal HD improved attention, working memory, and
processing speed after 6 months through less acute shifts in
cerebral circulation.27 However, a lack of patient incentive,
self-cannulation, and a change from familiar HD inpatient
8 M. Patel et al.facilities are obstacles of nocturnal HD from the nocturnal
dialysis trial.
Group-based cognitive behavioral intervention has been
used to improve adherence to HD fluid restriction with
significant changes in cognition key to this.28 The draw-
backs of group-based interventions include less time per
patient, inability to individualize interventions, and group
conflicts. Kidney transplantation has also been shown to
improve cognition 1 year following transplantation, but
<5% of HD patients receive a transplant every year29 and
this is not a viable option for the majority of HD patients.
Exercise has also been shown to improve cognition in an
observational study with 102 patients, and alongside
cognitive behavioral therapy improves physical function.30
However, increasing the frequency of HD does not
significantly improve cognition, and short daily HD sessions
also had no effect on cognition.31Cognitive stimulation in chronic diseases
Chronic diseases such as heart failure, chronic obstructive
pulmonary disease, and cancer have also been associated
with CI. No evidence is currently available in the literature
looking at CSTs in HD patients.
Cancer-related CI has been a significant area of
research, with up to 50% of survivors exhibiting mild to
moderate CI following chemotherapy.32 Pharmacological
stimulant therapies with methylphenidate and modafinil in
breast cancer have been shown to improve cognition.33
However, such agents are associated with an associated
risk of strokes and myocardial infarcts, with limited avail-
able data on its use in chronic renal disease. Non-
pharmacological techniques include meditation,
acupuncture, and consumption of antioxidant-rich foods.
Animal models have shown an improvement in renal func-
tion with both acupuncture and antioxidants.34
Memory and attention adaptation training in 29 treated
breast cancer patients improved cognitive performance up
to 6 months after completion.35 However, one study
compared both group and individual cognitive training, and
found no significant difference in cognitive functions,36
although the timing of assessment, with spontaneous re-
turn of cognition postchemotherapy, might have led to this
finding.
In HIV, damage to the central nervous system with im-
mune activation and viral proteins has been postulated to
lead to CI. An Internet-based cognitive stimulation program
lasting over 24 weeks showed significant improvement in
cognition.37 In patients with HIV who received speed of
processing training, they bettered on a scale of visual speed
of processing, indicative of neuroplasticity.38 Captain’s Log
modules in Ugandan children resulted in significant im-
provements in attention and processing speed.39
In heart failure, optimization of medical therapy with
the use of ace inhibitors and beta-blockers has been shown
to improve cognition.40 These agents may also improve the
cardiovascular risk factors in HD patients alongside a
possible benefit in cognition.
In chronic obstructive pulmonary disease, exercise
alongside education has been shown to improve cogni-
tion.41 With the median age being 66 for HD patients,comorbidities will limit their exercise capacity; moreover,
education will require adequate residual cognitive func-
tioning. However, cognitive training was not found to be
effective.42
CSTs have been shown to improve cognition in patients
with dementia, comparable with anticholinesterase in-
hibitors, and in combination was more effective than
anticholinesterase inhibitors alone.43 The Advanced Cogni-
tive Training for Independent and Vital Elderly trial
involving 2000 patients showed that at 5-year follow-up
following cognitive training in elderly patients, there was
an improvement in cognition and less decline in activities of
daily living.44 A Kinect-based exercise game improved ex-
ecutive cognition in 41 elderly Japanese patients.45
Cognitive stimulation therapy
Psychological therapies have increasingly been used for CI
and dementia through interventions such as cognitive
rehabilitation and cognitive training. A systematic review
determined that CST had the strongest evidence for
cognitive improvement.46 CST is a psychological interven-
tion in those with CI to improve cognition as well as social
skills. CST is a twice-weekly, 7-week course of 45-minute
activities, which involves organized discussions either
individually or in small groups of five to eight by specialist
trained staff.47 An UK randomized control trial involving 201
patients with dementia also showed cognitive improvement
with a CST program.48 The limitations of this study were
time constraints and exclusion of patients unable to com-
plete assessments.
CST has been recommended by the National Institute for
Health and Care Excellence in the United Kingdom for use in
mild to moderate dementia. The long-term benefit of CST is
currently unknown, although one study found that patients
showed an improvement with ongoing CST at 6 months.49
Qualitatively, patients have also reported positive
changes with everyday activities. Family caregivers do not
benefit from group CST, although individual CST has been
shown to improve carer wellbeing.50
Conclusion
Overall, despite CI being a known consequence of chronic
diseases, limited treatments are available to slow down this
decline in cognition. CST has been shown to be beneficial in
patients with known dementia; however, no previous
studies have used CST for HD patients with CI. There is a
need to investigate whether CST has any effect on cognition
in HD patients both in short term, with respect to activities
of daily living, and in long term, with respect to the pos-
sibility of reducing the risk of dementia.
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